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Abstract The endothelial protein p331gClqR is thought to 
mediate the assembly of components of the kinin-forming and 
complement-activating pathways on the surface of cardiovascular 
cells. FACS analysis of intact human umbilical vein endothelial 
cells using specific antibodies to p33 revealed a minor 
fluorescence on the cell surface whereas permeabilized cells 
showed a bright fluorescence indicative of an intracellular 
localization of p33. Immunostaining of fixed cells confirmed 
the predominant intracellular localization of p33. Fractionation 
studies demonstrated that the vesicular but not the membrane 
fraction of EA.hy926 cells is rich in p33. We conclude that 
externalization of p33 must precede its complex formation with 
target proteins on the endothelial cell surface. 
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1. Introduction 
The assembly of hormone precursors on the surface of their 
I trget cells serves to secure the rapid and efficient release of 
t ae corresponding peptide hormones at or next to their site of 
~ction. This principle is exemplified by the kinin and the com- 
Flement systems which are systemically available but locally 
~ cting. To facilitate the circumscribed release of effectors uch 
~.s bradykinin and C5a in situ, target cells expose docking 
],roteins that bind the interacting components of these systems 
~,nd assemble them on cellular surfaces. The nature and func- 
tion of such docking proteins has long been obscure. Recently 
we and others have identified a major kininogen binding pro- 
tzin, p33 of endothelial cells [1,2], that binds to H-kininogen 
with high affinity (9 nM) and anchors preformed H-kinino- 
~en-prokallikrein complexes to endothelial cell surfaces [3,4]. 
']'he same protein, gClqR,  serves as a 'receptor' for the glob- 
~4ar heads of the complement component C lq  and has been 
,laimed to assemble the early complement factors on the sur- 
lace of lymphocytes and neutrophils [5,6]. This latter view has 
heen challenged by the recent observation of an intracellular 
9calization of gC lqR  in Raji and mesangial cells [7]. We 
wondered whether this phenomenon also extends to endothe- 
lial cells, the key players in the kinin-forming pathway of the 
ardiovascular system. Here we demonstrate that p33/gClqR 
almost exclusively localized in intracellular vesicles of en- 
dothelial cells, and conclude that externalization must precede 
~nteraction of p33/gClqR with kininogen on the endothelial 
~ell surface. 
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2. Materials and methods 
2.1. Production and immunoselection f antibodies 
Antisera to synthetic peptides or to recombinant p33 were raised in 
rabbit [8]. Peptide CHT28 of 28 residues derived from the NH2-ter- 
minal portion of mature p33 was synthesized by the solid phase 
method. Recombinant p33 was expressed in E. coli in the form of a 
fusion protein with bacterial maltose binding protein (MBP), and 
purified as described [1]. The resultant antisera were tested with an 
indirect ELISA using free peptides (2 pg/ml) or recombinant p33 
(0.5 ~tg/ml) as the coating antigen. For immuno-affinity chromatog- 
raphy peptide CHT28 (4 mg/ml) or recombinant p33 (2 mg/ml) were 
covalently coupled to Affi-Gel 10. 
2.2. Cell culture 
Human umbilical vein endothelial cells (HUVEC) were prepared 
according to Jaffe et al. [9]. EA.hy926 cells [10] were grown in Dul- 
becco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose, 
10% (v/v) fetal bovine serum, 100 tiM hypoxanthine, 0.4 ~tM amino- 
pterin, 16 ~tM thymidine, and antibiotics in a humidified 5% CO2 
atmosphere at 37°C. 
2.3. Fluorescence-activated c llsorting ( FA CS) 
Confluent HUVEC or EA.hy926 cells were removed from dishes 
with phosphate-buffered saline (PBS), pH 7.4, 0.5 mM EDTA, and 
washed 2x with ice-cold PBS, 0.5% (w/v) bovine serum albumin 
('incubation buffer'). Cells (1 x 106) were suspended in incubation buf- 
fer containing antiserum at 1:100 (v/v) for 1 h at 4°C, washed 3x,  
and resuspended in incubation buffer containing fluorescein isothio- 
cyanate (FITC)-conjugated goat anti-rabbit Ig at 1:100 (v/v). Cells 
were incubated (1 h, 4°C), washed 3 x, fixed with 4% (v/v) formalde- 
hyde, and analyzed by FACScan (Becton Dickinson) and the Lysis II 
program. Alternatively the cells were fixed with 4% formaldehyde 
prior to antibody exposure. For permeabilization fixed cells were 
washed 2x with PBS and incubated with 0A% Triton X-100 in 
PBS (5 rain, 25°C). 
2.4. Immunofluorescence studies of HUVEC and E4.hy926 cells 
HUVEC or EA.hy926 cells were grown on chamber slides (Nunc). 
The cells were washed 2 X with ice-cold PBS and fixed with 4% for- 
maldehyde. For membrane permeabilization the cells were treated 
with ice-cold methanol for 10 min. After washing 3 x with PBS, the 
cells were incubated (30 min, 37°C) with 20 Ixg/ml antibody in PBS, 
0.5% bovine serum albumin. The cells were washed and incubated (30 
min, 37°C) with FITC-conjugated goat anti-rabbit Ig at 1 : 100 (v/v) in 
the same buffer. After 3 washes with PBS, the cells were embedded in
n-propyl gallate and viewed with an Axiophot microscope (Zeiss). 
2.5. Cell fractionation 
EA.hy926 cells were grown to confluence on 24 cm dishes, washed 
twice with ice-cold PBS, and scraped from the plates in 50 mM phos- 
phate, pH 7.4, 0.28 M sucrose, 10 ~tg/ml phenylmethylsulfonyl fluor- 
ide, 10 ~tg/ml benzamidine.HC1. The cells were homogenized (Ultra- 
Turrax, Janke and Kunkel, Germany) with 2 strokes of 15 s each. The 
homogenate was centrifuged (800xg, 10 min), the nuclear pellet Pl 
was discarded, and the supernatant $1 was centrifuged again 
(30000xg, 20 min). Supernatant $2 was collected, the membrane 
pellet P2 was washed with 50 mM phosphate, pH 7.4, and resus- 
pended in the same buffer containing 12% (w/v) sucrose. An aliquot 
(1 ml) was layered on top of a 33% sucrose cushion (11 ml) and 
centrifuged (100000xg, 3 h). The pellet P3 (vesicular fraction) was 
resuspended in phosphate buffer. The membranes at the gradient in- 
terface were collected, diluted with 50 mM phosphate, pH 7.4 and 
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centrifuged (30000 x g, 45 min) [11]. Pellet P4 (membrane fraction) 
was resuspended in phosphate buffer. Centrifugation (100000xg, 
3 h) of supernatant $2gave pellet P~ (microsomal fraction) and super- 
natant $3 (cytosolic fraction). All manipulations were done at 4°C, 
and the cellular fractions were stored at -80°C until use. 
2.6. Gel electrophoresis and immunoblotting 
Harvested cells or cellular fractions were dissolved in sample buffer 
(63 mM Tris-HCl, pH 6.8, 2.5% SDS, 5% glycerol, 5% 2-mercap- 
toethanol, 0.005% bromophenol b ue) for 30 min at 42°C, followed 
by SDS-PAGE on linear 12% (w/v) polyacrylamide g ls. The sepa- 
rated proteins were electrotransferred to nitrocellulose membranes 
according to the manufacturer's in tructions (Schleicher and Schuell). 
Immunoprints were done with 0.5-1 ~tg/ml of purified antibody apply- 
ing the chemiluminescence m thod with a horseradish peroxidase-la- 
beled secondary antibody at 1:5000. 
2.7. lmmunoprecipitation f 35S-labeled p33 
Confluent EA.hy926 cells were washed with Cys/Met-free DMEM, 
and incubated with the same medium (1 h, 37°C), The cells were 
labeled with 100 gCi/ml [35S]Cys/Met (6 h, 37°C). The cell culture 
medium was harvested, adjusted to 10 mM EDTA, l0 gg/ml phenyl- 
methylsulfonyl fluoride, 10 gg/ml benzamidine.HCl, and centrifuged 
(14000xg, 10 min). The supernatant was transferred to a fresh tube 
and incubated under otation (1 h, 4°C) with 10 gl anti-p33 bound to 
Staphylococcus A cells (Calbiochem). The mixture was centrifuged 
(8000Xg, 2 min, 4°C), and the precipitate washed 4× in 150 mM 
NaC1, 50 mM Tris-HCl, pH 8.0, 0.1% SDS, 0.5% deoxycholic acid, 
1% Nonidet P-40, 10 Bg/ml phenylmethylsulfonyl fluoride, 10 Bg/ml 
benzamidine-HCl ('RIPA'). The labeled cells were washed 2 x with 
ice-cold PBS, lysed in RIPA buffer under rotation (1 h, 4°C), and 
centrifuged (14000Xg, 10 min, 4°C). The supernatant was treated 
with anti-p33 as above. The precipitates were dissolved in sample 
buffer and run on SDS-PAGE. The fixed gel was incubated with 
15% sodium salicylate (30 rain, 25°C), dried (2 h, 60°C) and exposed 
to a Fuji X-ray film (12 h, -80°C). 
3. Results 
Antisera to recombinant p33 fused to MBP (anti-p33) or to 
the synthetic peptide CHT28 derived from the NH2-terminus 
of mature p33 (anti-CHT28) were raised in rabbits. The spe- 
cificity of the affinity-purified antibodies was assessed by im- 
munoblotting using total cellular extracts of HUVEC, 
EA.hy926 cells, or from E. coli expressing the MBP-p33 fu- 
sion protein (Fig. 1). A single 33 kDa band of HUVEC or 
67b 
43 ~' 
30~ 
201~ 
112131,121o 
i 
g Q 
1,181, 
- - - -  
° 
470  k 
33 k 
Fig. 1. Specificity of anti-p33 and anti-CHT28 demonstrated by 
Western blotting. Total cellular extracts (30 ~ag) of HUVEC (lanes 
1 3) or EA.hy926 cells (lanes 4%) were probed by preimmune sera 
at 1:1000 (lanes 1, 4), 0.5 ~tg/ml anti-p33 (lanes 2, 5), or 1 ~tg/ml 
anti-CHT28 (lanes 3, 6). For control, MBP-p33 present in total cel- 
lular extracts of E. coli was probed with preimmune serum (lane 7), 
anti-p33 (lane 8), or anti-CHT28 (lane 9). The molecular masses of 
standard (p33) proteins are indicated on the left (right). 
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Fig. 2. FACS analysis of p33 expression on the surface of HUVEC 
(A) and EA.hy926 cells (B). Intact HUVEC and EA.hy926 cells 
were incubated with (1) preimmune serum, (2) anti-p33, or (3) per- 
meabilized with 0.1% Triton X-100 and incubated then with anti- 
p33. The antiserum dilution was 1:100, and a secondary FITC-la- 
beled antibody was used throughout. 
EA.hy926 cell extracts was visualized by anti-p33 and by anti- 
CHT28 whereas the corresponding preimmune serum was 
negative (Fig. 1, lanes 1-6). In total cell extracts of E. coli a 
70 kDa fusion protein of p33 and MBP was recognized by 
anti-p33 and anti-CHT28 but not by preimmune serum (Fig. 
1, lanes 7-9). Hence anti-p33 and anti-CHT28 antibodies pe- 
cifically and sensitively detect p33 in complex cellular extracts. 
To test the cellular localization of p33, we performed FACS 
analyses of intact HUVEC (Fig. 2A) and EA.hy926 cells (Fig. 
2B); preimmune serum served as the control. A minor in- 
crease in fluorescence intensity was seen with intact cells as 
compared to the control, whereas pretreatment of the cells 
with Triton X-100 markedly shifted the fluorescence signal 
to higher intensities. Similar results were obtained with anti- 
CHT28 (not shown). These data indicate that only a minor 
amount of p33 is accessible on the surface of endothelial cells 
whereas the vast majority of p33 is located within the cell 
borders. 
To address the intracellular localization of p33, immuno- 
fluorescence studies were performed. Confluent monolayers of 
HUVEC or EA.hy926 cells were fixed, permeabilized, and 
stained with the anti-p33 (Fig, 3B-D) or preimmune serum 
(Fig. 3A). Both cell types showed a punctuate labeling juxta- 
posed to the nucleus whereas the cell surface was almost free 
of staining, suggesting that p33 is present in vesicles and not 
freely accessible in the cytoplasm. 
The subcellular localization of p33 was further examined by 
fractionation of EA.hy926 cell homogenates. Equal amounts 
of protein from the various cell fractions were subjected to 
Western blotting using anti-p33 (Fig. 4A, upper panel). A 33 
kDa band was found in the total cellular extract of EA.hy926 
cells (lane 1), in the cytoplasm (lane 2), in the microsomal 
fraction (lane 3), and most prominently in their vesicular frac- 
tion (lane 5). By contrast he membrane fraction of EA.hy926 
cells was almost free of p33 (lane 4). To verify the fractiona- 
tion procedure we used a monoclonal antibody to a plasma 
membrane-associated enzyme, endothelial nitric oxide 
synthase (NOSIII, Affinity, Nottingham, UK). Unlike p33 
the majority of NOSIII  is present in the membrane fraction 
(Fig. 4A, lower panel), and the corresponding vesicular frac- 
tion is virtually free of the enzyme. These findings underline 
our notion that under the conditions of our experiments the 
majority of p33 is stored in intracellular vesicles whereas the 
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Fg. 3. Immunofluorescence of p33. EA.hy926 cells were incubated with preimmune serum at 1:100 (A) or with 20 pg/ml anti-p33 (B, C), and 
HUVEC with 20 pg/ml anti-p33 (D). Magnification ×40 (A, B), × 100 (C, D). 
3, kDa band in the cytosolic fraction likely reflects lysis or 
n echanical disruption of vesicles during cell fractionation. 
We asked if p33 is secreted from endothelial cells. To this 
eud EA.hy926 cells were metabolically abeled with 3~S-amino 
a .ids, and immunoprecipitates were analyzed by SDS-PAGE 
a id  autoradiography (Fig. 4B). A major 33 kDa band and a 
ninor 31 kDa band were immunoprecipitated from total cell 
1.~ sates by anti-p33 (Fig. 4B, lane 2). These bands waned upon 
p'eincubation of anti-p33 with 100 gg MBP-p33 (lane 3), 
s tggesting that the 31 kDa band represents a p33 degradation 
p.-oduct of EA.hy926 cells. Preimmune serum failed to pro- 
dace specific bands (lane 1). Unlike the cell lysate, the culture 
n,edium was virtually free of significant amounts of p33 (lane 
4 ~, indicating that EA.hy926 cells do not constitutively secrete 
s gnificant amounts of newly synthesized p33 into the me- 
OHm. 
4 Discussion 
In the present study, we have examined the localization of 
t ~e kininogen binding protein, p33/gClqR, in primary cul- 
t tres of HUVEC and in a hybrid cell line, EA.hy926. Three 
i~ldependent approaches using two distinct antibodies together 
lead to the conclusion that p33 is primarily localized in intra- 
cellular stores, and at best a minor part of it is exposed on the 
surface of these endothelial cells. This finding is unexpected 
because (i) p33/gClqR has been shown by immunohistochem- 
istry to be almost exclusively localized on the surface of B 
cells [5], neutrophils [6] and mast cells [12]; (ii) p33/gClqR 
has the features of a secretory protein that is likely to be 
exported to the exterior of the cell [5]; and (iii) the demon- 
strated capacity of p33/gClqR to interfere with kininogen 
binding to endothelial cell surfaces [1,2]. One possible expla- 
nation for the observed intracellular localization in endothe- 
lial cells is that under the conditions of cell culturing p33 is 
synthesized and transiently stored in vesicles from which it 
translocates to the plasma membrane by hitherto unknown 
stimuli. However, we have been unable to promote p33 trans- 
location by bradykinin (data not shown) which increases the 
number of kininogen binding sites present on endothelial cells 
[13]. On the other hand, we cannot exclude the distinct pos- 
sibility that p33 is a docking protein that is transiently ex- 
posed on the cell surface and rapidly internalized to import 
kininogen and possibly Clq into protected compartments of
the endothelial cell. Indeed, van lwaarden and coworkers have 
reported the internalization of surface-bound kininogen by 
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l ig. 4. A. Immunoprinting of p33 in subcellular fractions of EA.hy926 cells. Protein (20 pg per lane) from total cellular extract (lane 1), cyto- 
s,)lic fraction Sa (lane 2), mierosomal fraction P5 (lane 3), membrane fraction P4 (lane 4), or vesicular fraction ,°3 (lane 5) were probed with 
0 5 gg/ml anti-p33 (upper panel) or anti-NOSIlI at 1:1000 (lower panel). B: Immunoprecipitation of p33. EA.hy926 cells were labeled with 100 
pCi/ml of [35S]Cys/Met. Total cellular extracts (lanes 1-3) or culture medium (lane 4) were probed with preimmune serum at 1:100 (lane 1), 
anti-p33 (lanes 2, 4)° or anti-p33 preabsorbed with 100 pg/ml of MBP-p33 (lane 3). Immune complexes were recovered with Staphylococcus A 
cells. Molecular masses of the relevant proteins are indicated in the margins. 
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endothelial cells [14] but others have challenged this finding 
[15]. Our present efforts are directed towards the precise sub- 
cellular localization of p33. Identification of the cell compart- 
ment(s) containing p33 might provide us with new insights 
into the functional roles and modes of action of this versatile 
protein. 
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